Compare Datadog Inc (DDOG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs Novartis AG — how do they compare? Datadog Inc trades at $274.19 (market cap $97.43B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 2.8× Datadog Inc's market cap, and Novartis AG pays a 3.31% dividend while Datadog Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and Novartis AG for 82 Days on average.
| DDOG | NVS | |
|---|---|---|
Market Cap | $97.43B | $274.00B |
Volume | 1,586,926 | 1,852,137 |
Sector | Technology | Health |
52-Week High | $288.15 | $168.62 |
52-Week Low | $102.62 | $121.80 |
Typical Hold Time | 76 Days | 82 Days |
Enterprise Value | $93.72B | $315.32B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $273.8, down 1.6% on the day, yet maintains a bullish technical stance with strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth remains robust, climbing from $1.7B in 2022 to $3.4B in 2025, though net income margins are volatile. Positive sentiment is fueled by AI-driven demand and global expansion, as highlighted in recent financial media.
The outlook is cautiously optimistic given high valuation multiples (P/E 542.68) and negative net cash flow, but strong revenue growth and a dominant buy rating consensus (83.34%) suggest upside to the $276.10 price target. Key risks include competitive pressures and reliance on enterprise cloud spending cycles.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
